Abstract
Peptidomimitism is applied to the medicinal chemistry in order to synthesize drugs that devoid of the disadvantages of peptides. AT1 antagonists constitute a new generation of drugs for the treatment of hypertension designed and synthesized to mimic the C-terminal segment of Angiotensin II and to block its binding action on AT1 receptor. An effort was made to understand the molecular basis of hypertension by studying the conformational analysis of Ang II and its derivatives as well as the AT1 antagonists belonging to SARTANs class of molecules. Such studies offer the possibility to reveal the stereoelectronic factors responsible for bioactivity of AT1 antagonists and to design and synthesize new analogs. An example will be given which proves that drugs with better pharmacological and financial profiles may arise based on this rational design.
Keywords: Antihypertensive Drugs, AT1 antagonists, C-terminal segment
Current Topics in Medicinal Chemistry
Title: Conformation and Bioactivity. Design and Discovery of Novel Antihypertensive Drugs
Volume: 4 Issue: 4
Author(s): T. Mavromoustakos, M. Zervou, P. Zoumpoulakis, I. Kyrikou, N. P. Benetis, L. Polevaya, P. Roumelioti, N. Giatas, A. Zoga and P. Moutevelis Minakakis
Affiliation:
Keywords: Antihypertensive Drugs, AT1 antagonists, C-terminal segment
Abstract: Peptidomimitism is applied to the medicinal chemistry in order to synthesize drugs that devoid of the disadvantages of peptides. AT1 antagonists constitute a new generation of drugs for the treatment of hypertension designed and synthesized to mimic the C-terminal segment of Angiotensin II and to block its binding action on AT1 receptor. An effort was made to understand the molecular basis of hypertension by studying the conformational analysis of Ang II and its derivatives as well as the AT1 antagonists belonging to SARTANs class of molecules. Such studies offer the possibility to reveal the stereoelectronic factors responsible for bioactivity of AT1 antagonists and to design and synthesize new analogs. An example will be given which proves that drugs with better pharmacological and financial profiles may arise based on this rational design.
Export Options
About this article
Cite this article as:
Mavromoustakos T., Zervou M., Zoumpoulakis P., Kyrikou I., Benetis P. N., Polevaya L., Roumelioti P., Giatas N., Zoga A. and Minakakis Moutevelis P., Conformation and Bioactivity. Design and Discovery of Novel Antihypertensive Drugs, Current Topics in Medicinal Chemistry 2004; 4 (4) . https://dx.doi.org/10.2174/1568026043451302
DOI https://dx.doi.org/10.2174/1568026043451302 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Malignant Hypercalcemia
Current Medicinal Chemistry A Review of Inadequate and Excessive Weight Gain in Pregnancy
Current Women`s Health Reviews Angina in Women without Obstructive Coronary Artery Disease
Current Cardiology Reviews <i>Ajuga</i> L.: A Systematic Review on Chemical Composition, Phytopharmacological and Biological Potential
Current Bioactive Compounds Female Infertility and Antioxidants
Current Women`s Health Reviews Targeting Tau Hyperphosphorylation <I>via</I> Kinase Inhibition: Strategy to Address Alzheimer's Disease
Current Topics in Medicinal Chemistry Biological Active Peptides from Marine Sources Related to Gut Hormones
Current Protein & Peptide Science Vitamin D and Cardiovascular Disease
Current Vascular Pharmacology The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research Fenofibrate: Metabolic and Pleiotropic Effects
Current Vascular Pharmacology Proteomics to Unravel Platelet-Related Diseases and Identify Novel Anti-Platelet Drugs
Current Medicinal Chemistry Methods for Identifying Cardiovascular Agents: A Review
Recent Patents on Cardiovascular Drug Discovery The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design Fine Tuning of PPAR Ligands for Type 2 Diabetes and Metabolic Syndrome
Mini-Reviews in Medicinal Chemistry Leveraging NMR and X-ray Data of the Free Ligands to Build Better Drugs Targeting Angiotensin II Type 1 G-Protein Coupled Receptor
Current Medicinal Chemistry Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art and New Perspectives with Patents Recently Applied
Recent Patents on Anti-Cancer Drug Discovery PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk
Current Pharmaceutical Design The Pathophysiology of CTGs and Types of Intrapartum Hypoxia
Current Women`s Health Reviews Vasospastic Angina and Ca Channel Blockers
Current Hypertension Reviews The Critical Role of Abnormal Trophoblast Development in the Etiology of Preeclampsia
Current Pharmaceutical Biotechnology